Know Labs, Inc. Discusses Significant Growth of Its IP Portfolio and 2023 Goals with The Stock Day Podcast
The Stock Day Podcast welcomed Know Labs, Inc.(KNW)(“the Company”), an emerging developer of non-invasive medical diagnostic technology. The Company refers to its novel technology as Bio-RFID™ which directs electromagnetic energy in the form of radio waves through organic or inorganic materials to capture a unique molecular signature. CEO and Chairman of the Company, Ron Erickson, joined Stock Day host Kevin Davis.
Davis began the interview by asking about the Company’s background and current projects. “At Know Labs, we have invented a sensor technology, which uses radio frequency to non-invasively ascertain the presence and amount of various analytes and molecules in the human body,” shared Erickson. “Our very first focus is monitoring blood glucose levels non-invasively,” he explained. “We are focused on the large global market of people that have type I and type II diabetes, as well as prediabetes.”
Davis then asked about the Company’s achievements over the last year. “A significant event occurred for us in September of last year when we uplisted to the New York Stock Exchange, where we now trade under the stock symbol ‘KNW’,” said Erickson, adding that the uplist created better visibility and more financial opportunities for the Company. “In terms of research, we have been doing a tremendous amount of research with our Bio-RFID sensor,” he shared. “As we’ve indicated, the sensor part of our technology is complete and has been used for internal clinical testing where research has been reported with two significant events.”
“The research we conducted in collaboration with the Mayo Clinic is now public and has been published in a peer-review journal,” continued Erickson. “The research has also been presented at two major medical conferences,” he added. “We are conducting clinical research every day and refining and analyzing the data gathered by our sensor in a way that will meet all FDA clearance standards.”
“Could we discuss IP development and what it means for the progression of your technology?”, asked Davis. “IP is a very important asset in any technology company,” said Erickson. “We have publicly announced that our total patents, issued and pending, is 159, which is a significant increase from last year,” he said. “Patents are important and we will continue to file patents, however we also continue to build a larger body of trade secrets, which drive our analysis of the data we have attained.”
“What can listeners and shareholders expect from Know Labs for the rest of 2023?”, asked Davis. “We plan on continuing to grow our IP portfolio, as well as add to our growing body of peer-reviewed and externally validated results from our Bio-RFID technology,” said Erickson. “The sensor will also find its place as part of a product or device, he added, to which we will then see an even more robust development of clinical research and validation, as well as a development of the product that allows it to come to market.”
To close the interview, Erickson encouraged listeners and shareholders to keep up-to-date on the Company’s current and upcoming projects as they continue to advance their development towards the first non-invasive glucose monitoring device, and move closer to delivering on their purpose of improving the lives of billions of people living with diabetes and prediabetes.
To hear Ron Erickson’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/8307093-know-labs-inc-discusses-significant-growth-of-its-ip-portfolio-and-2023-goals-with-the-stock-da
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2022, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005308/en/
For Know Labs Media Inquiries Contact:
Ph. (603) 494-6667
Know Labs, Inc. Contact:
Ph. (206) 629-6414
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
Stock Day Media